solriamfetol
Nervous system (N06)US regulatory status: approved.
pharma · Sleep Apnea, Obstructive
Ignis Therapeutics (Suzhou)
Ignis Therapeutics (Suzhou) Limited
Ignis Therapeutics (Suzhou) drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Ignis Therapeutics (Suzhou) pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Ignis Therapeutics (Suzhou) drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.